The use of mitoxantrone plus cyclophosphamide as first‐line treatment of metastatic breast cancer

Werner R. Bezwoda, Charles Hesdorffer

Research output: Contribution to journalArticle

Abstract

Thirty‐two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus Cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty‐one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + Cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)1621-1624
Number of pages4
JournalCancer
Volume58
Issue number8
DOIs
StatePublished - Oct 15 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The use of mitoxantrone plus cyclophosphamide as first‐line treatment of metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this